Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients ... same treatment class can ...

Fasenra (benralizumab) is a brand-name subcutaneous injection that’s prescribed for severe eosinophilic asthma in certain people. Fasenra hasn’t been reported to interact with alcohol, other ...

September 18, 2024--(BUSINESS WIRE)--AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food and Drug Administration (FDA ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...

(RTTNews) - AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with ...

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: “FASENRA is already ... on emerging science involving immune mechanisms, lung damage and abnormal ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...

The safety and tolerability profile for Fasenra in the MANDARA trial was consistent with the known profile of the medicine. 4 Approximately half of patients with EGPA have adult-onset severe ...

WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with ...